Oncology Division
Alphabetical list (active faculty):   
Amanda M. Smith

Amanda M. Smith, PhD


Department of Medicine

Oncology Division

Stem Cell Biology

Research Interests

  • Mechanisms of leukemia initiation
  • Epigenetic states and the way they affect leukemia growth
  • Cancer genomics and mouse models


  • 314-362-8832 (office)
  • 314-362-9333 (fax)
  • Division of Oncology
    Campus Box 8007
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Room 626 Southwest Tower (office)

Peer-reviewed Manuscripts

  • Dnmt3a Deficiency in the Skin Causes Focal, Canonical DNA Hypomethylation and a Cellular Proliferation Phenotype
    Chen DY, Ferguson IM, Braun KA, Sutton LA, Helton NM, Ramakrishnan SM, Smith AM, Miller CA, Ley TJ
    Proc Natl Acad Sci U S A 2021 Apr 20;118(16):e2022760118
  • Remethylation of Dnmt3a (-/-) Hematopoietic Cells Is Associated With Partial Correction of Gene Dysregulation and Reduced Myeloid Skewing
    Ketkar S, Verdoni AM, Smith AM, Bangert CV, Leight ER, Chen DY, Brune MK, Helton NM, Hoock M, George DR, Fronick C, Fulton RS, Ramakrishnan SM, Chang GS, Petti AA, Spencer DH, Miller CA, Ley TJ
    Proc Natl Acad Sci U S A 2020 Feb 11;117(6):3123-3134
  • PTEN Deletion Drives Acute Myeloid Leukemia Resistance to MEK Inhibitors
    Smith AM, Zhang CRC, Cristino AS, Grady JP, Fink JL, Moore AS
    Oncotarget 2019 Oct 8;10(56):5755-5767
  • Haploinsufficiency for DNA Methyltransferase 3A Predisposes Hematopoietic Cells to Myeloid Malignancies
    Cole CB, Russler-Germain DA, Ketkar S, Verdoni AM, Smith AM, Bangert CV, Helton NM, Guo M, Klco JM, O'Laughlin S, Fronick C, Fulton R, Chang GS, Petti AA, Miller CA, Ley TJ
    J Clin Invest 2017 Oct 2;127(10):3657-3674
  • Activation of Protein Phosphatase 2A in FLT3+ Acute Myeloid Leukemia Cells Enhances the Cytotoxicity of FLT3 Tyrosine Kinase Inhibitors
    Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, Panicker N, Mashkani B, Don AS, Morris J, Toop H, Lock RB, Powell JA, Thomas D, Guthridge MA, Moore A, Ashman LK, Skelding KA, Enjeti A, Verrills NM
    Oncotarget 2016 Jul 26;7(30):47465-47478
  • Targeting Survivin With YM155 (Sepantronium Bromide): A Novel Therapeutic Strategy for Paediatric Acute Myeloid Leukaemia
    Smith AM, Little EB, Zivanovic A, Hong P, Liu AK, Burow R, Stinson C, Hallahan AR, Moore AS
    Leuk Res 2015 Apr;39(4):435-44
  • Essential Requirement for PP2A Inhibition by the Oncogenic Receptor c-Kit Suggests PP2A Reactivation as a Strategy to Treat c-Kit+ Cancers
    Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, Sim AT, Ashman LK, Verrills NM
    Cancer Res 2010 Jul 1;70(13):5438-47

Invited Publications

  • Vincristine Sulfate Liposomal Injection for Acute Lymphoblastic Leukemia
    Raj TA, Smith AM, Moore AS
    Int J Nanomedicine 2013;8:4361-9
  • Ser/Thr Phosphatases: A New Frontier for Myeloid Leukemia Therapy?
    Smith AM, Roberts KG, Verrills NM
    In: Myeloid Leukemias - Basic Mechanisms of Leukemogenesis (Koschmieder S, Utz K, Eds), 2011